Mark Gallant



  • Monday, March 1, 2004
    Editor: What is the current climate in the biotech/pharma industries as far as capital? Heller: Over the last year, we have seen more deal flow and venture funding. I attribute this to more optimism in the public markets, venture funds wanting to get off the sidelines as they have been for a couple years, recent successful closings on capital raises for...